Genprex, Inc. (NASDAQ:GNPX) Short Interest Update

Genprex, Inc. (NASDAQ:GNPX) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 1,130,000 shares, a growth of 505.2% from the January 31st total of 186,700 shares. Based on an average daily volume of 920,700 shares, the short-interest ratio is currently 1.2 days. Currently, 13.7% of the company’s shares are sold short.

Genprex Trading Up 0.5 %

GNPX stock traded up $0.00 during mid-day trading on Friday, reaching $0.38. The company’s stock had a trading volume of 469,464 shares, compared to its average volume of 1,018,017. Genprex has a 12 month low of $0.28 and a 12 month high of $5.41. The business’s 50 day moving average price is $0.64 and its 200 day moving average price is $0.85.

Institutional Investors Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Geode Capital Management LLC lifted its stake in shares of Genprex, Inc. (NASDAQ:GNPX) by 368.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,045 shares of the company’s stock after purchasing an additional 59,798 shares during the quarter. Geode Capital Management LLC owned about 0.89% of Genprex worth $65,000 at the end of the most recent reporting period. 14.05% of the stock is owned by institutional investors and hedge funds.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.